Translate Bio’s (TBIO) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Translate Bio (NASDAQ:TBIO) in a research note published on Monday morning, AnalystRatings.com reports. The brokerage currently has a $21.00 price objective on the stock.

“We remind investors that the company has importantly highlighted the MAD portion of the MRT5005 trial as representative of the first time multiple doses of an mRNA therapeutic have been utilized in patients for treating a genetic disease. This portion of the Phase 1/2 trial can also provide greater insight into MRT5005’s safety profile in the CF patient population. MRT5005 is the company’s mRNA therapeutic designed to treat CF patients using targeted liposome encapsulated nanoparticles delivered by nebulization. We continue to believe in the platform value of targeting protein or gene dysfunction through an mRNA focus, as it stands to directly address the functional protein deficiencies underlying the disease state.”,” the firm’s analyst wrote.

Separately, Zacks Investment Research lowered Translate Bio from a hold rating to a sell rating in a report on Saturday, April 20th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of Buy and an average price target of $22.75.

Shares of TBIO stock opened at $10.42 on Monday. Translate Bio has a 12-month low of $4.81 and a 12-month high of $16.60. The company has a market capitalization of $472.38 million and a P/E ratio of -2.86. The company has a debt-to-equity ratio of 0.83, a current ratio of 10.47 and a quick ratio of 10.47.

Translate Bio (NASDAQ:TBIO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.04). The company had revenue of $1.47 million during the quarter. Equities research analysts forecast that Translate Bio will post -1.52 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new stake in Translate Bio in the first quarter worth approximately $165,000. Oxford Asset Management LLP acquired a new stake in Translate Bio in the first quarter worth approximately $115,000. Voya Investment Management LLC acquired a new stake in Translate Bio in the first quarter worth approximately $123,000. Geode Capital Management LLC lifted its position in Translate Bio by 107.6% in the first quarter. Geode Capital Management LLC now owns 243,754 shares of the company’s stock worth $2,483,000 after purchasing an additional 126,322 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Translate Bio by 252.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 65,438 shares of the company’s stock worth $667,000 after purchasing an additional 46,848 shares during the period. Hedge funds and other institutional investors own 59.33% of the company’s stock.

About Translate Bio

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Recommended Story: What is a put option?

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.